VALIRX PLC LS-001
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more
Market Cap & Net Worth: VALIRX PLC LS-001 (EAJF)
VALIRX PLC LS-001 (F:EAJF) has a market capitalization of $381.23K (€371.40K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #39863 globally and #5729 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VALIRX PLC LS-001's stock price €0.00 by its total outstanding shares 742801072 (742.80 Million).
VALIRX PLC LS-001 Market Cap History: 2018 to 2026
VALIRX PLC LS-001's market capitalization history from 2018 to 2026. Data shows change from $9.53 Million to $381.23K (-66.92% CAGR).
VALIRX PLC LS-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VALIRX PLC LS-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EAJF by Market Capitalization
Companies near VALIRX PLC LS-001 in the global market cap rankings as of March 19, 2026.
Key companies related to VALIRX PLC LS-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VALIRX PLC LS-001 Historical Marketcap From 2018 to 2026
Between 2018 and today, VALIRX PLC LS-001's market cap moved from $9.53 Million to $ 381.23K, with a yearly change of -66.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €381.23K | -87.50% |
| 2025 | €3.05 Million | -46.67% |
| 2024 | €5.72 Million | -88.97% |
| 2023 | €51.85 Million | -55.56% |
| 2022 | €116.66 Million | -67.03% |
| 2021 | €353.78 Million | +120.95% |
| 2020 | €160.12 Million | +740.00% |
| 2019 | €19.06 Million | +100.00% |
| 2018 | €9.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of VALIRX PLC LS-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $381.23K USD |
| MoneyControl | $381.23K USD |
| MarketWatch | $381.23K USD |
| marketcap.company | $381.23K USD |
| Reuters | $381.23K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.